Related Experiment Videos

Postoperative emesis following otoplasty in children

D Paxton1, R H Taylor, T M Gallagher

  • 1Department of Anaesthesia, Royal Belfast Hospital for Sick Children, Northern Ireland.

Anaesthesia
|December 1, 1995
PubMed

Insights

Ondansetron significantly reduced vomiting and allowed earlier oral intake in children undergoing otoplasty compared to droperidol or placebo. This antiemetic offers a better post-operative recovery for pediatric surgical patients.

Area of Science:

  • Anesthesiology
  • Pediatric Surgery
  • Pharmacology

Background:

  • Postoperative nausea and vomiting (PONV) are common complications in pediatric surgery.
  • Effective antiemetic strategies are crucial for improving patient recovery and comfort.
  • Otoplasty is a common pediatric surgical procedure where PONV can impact recovery.

Purpose of the Study:

  • To compare the efficacy of ondansetron, droperidol, and placebo in preventing PONV in children undergoing otoplasty.
  • To evaluate the impact of these agents on the time to oral fluid and food ingestion post-surgery.

Main Methods:

  • A randomized controlled trial involving 60 unpremedicated children aged 3-14 years scheduled for otoplasty.
  • Patients were assigned to receive ondansetron (0.1 mg/kg), droperidol (75 mcg/kg), or placebo at anesthesia induction.
  • Standard general anesthesia with thiopental, atracurium, and halothane was administered, avoiding intraoperative opioids.

Main Results:

  • Ondansetron significantly reduced vomiting incidence (15%) compared to droperidol (40%) and placebo (60%) (p < 0.01).
  • Children receiving ondansetron tolerated oral fluids and solids earlier (p < 0.001).
  • No significant difference in vomiting or oral intake time was observed between droperidol and placebo groups.

Conclusions:

  • Ondansetron is an effective antiemetic for pediatric otoplasty, improving recovery by reducing nausea and vomiting.
  • Ondansetron facilitates earlier resumption of oral feeding compared to droperidol or placebo.
  • While a transient nodal rhythm was noted with ondansetron, it was not clinically significant, and no other adverse events were reported.

Related Concept Videos